Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2019) 65 P370 | DOI: 10.1530/endoabs.65.P370

SFEBES2019 POSTER PRESENTATIONS Reproductive Endocrinology and Biology (50 abstracts)

Hyperprolactinaemia resistant to dopamine agonist due to an ectopic source of prolactin arising from a Uterine Tumour Resembling Ovarian Sex Cord Tumours (UTROCST)

Sobia Arshad 1 , Mohammed Bakhit 2 , J Bidmead 3 , D Lewis 3 , S Diaz-cano 3 , Simon Aylwin 3 & Wajman Delane 3


1Medway Meritime Hospital, Kent, UK; 2Guys and St Thomas Hospital, London, UK; 3Kings College Hospital, London, UK


A 46 year old female presented with 12 months history of secondary amenorrhoea. Prolactin was 4746 mIU/l without macroprolactin complexes, LH & FSH were low, oestradiol was undetectable. She had normal visual fields. No other clinical or biochemical features of pituitary dysfunction. She had no regular medication. Pituitary MRI was normal. She was started on cabergoline 250 mcg twice weekly which was subsequently increased to 500 mcg twice weekly. Repeat serum prolactin 5 months and 8 months later showed a progressive rise to 6649 mIU/l and 9653 mIU/l respectively. Compliance with medication was confirmed. Repeat pituitary MRI scan was normal. An alternative source of prolactin was considered. Further clinical assessment revealed a palpable pelvic mass. Pelvic CT showed an 11 cm uterine mass which raised the possibility of an ectopic prolactin source. She underwent surgical resection. Histological examination showed a benign Uterine Tumour Resembling Ovarian Sex Cord Tumours (UTROSCT). Immunohistochemistry was negative for prolactin, however serum prolactin postoperatively reduced to 59 mIU/l and menstrual cycle returned.

Discussion: The notable features of this case were (1) the high prolactin with a normal MRI scan (2) A paradoxical rise in the serum prolactin after initiation of dopamine agonist therapy. Out of 8 previous reports of ectopic extra-cranial prolactin secretion in the published literature, there were three ovarian germ cell tumours (two teratomas, one dermoid) which showed microscopic pituitary elements. UTROSCTs are rare uterine neoplasms with the most recent literature review citing 77 cases. UTROSCTs have not been associated with hyperprolactinaemia prior to this report. However, two other cases have been reported with uterine tumours (one ‘fibroid’ and one ‘mesenchymal tumour’) which share characteristics with this case. Hyperprolactinaemia due to extra-cranial ectopic prolactin production is rare. Where suspected, the majority of ectopic prolactin-secreting tumours have been located in the ovaries and uterus.

Volume 65

Society for Endocrinology BES 2019

Brighton, United Kingdom
11 Nov 2019 - 13 Nov 2019

Society for Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.